{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:35:06Z","timestamp":1787960106396,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T00:00:00Z","timestamp":1491350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T00:00:00Z","timestamp":1491350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s40261-017-0523-2","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T16:47:27Z","timestamp":1491410847000},"page":"625-634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Current Clinical Trials on the Use of Ceftaroline in the Pediatric Population"],"prefix":"10.1007","volume":"37","author":[{"given":"Adam","family":"Corey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0821-6119","authenticated-orcid":false,"given":"Tsz-Yin","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,5]]},"reference":[{"key":"523_CR1","doi-asserted-by":"publisher","first-page":"e52722","DOI":"10.1371\/journal.pone.0052722","volume":"8","author":"VM Dukic","year":"2013","unstructured":"Dukic VM, Lauderdale DS, Wilder J, et al. Epidemics of community-associated methicillin-resistant Staphylococcus aureus in the United States: a meta-analysis. PLoS One. 2013;8:e52722.","journal-title":"PLoS One"},{"key":"523_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.yapd.2008.07.004","volume":"55","author":"S Elliott","year":"2008","unstructured":"Elliott S. Antimicrobial-resistant pathogens: an emerging pediatric threat. Adv Pediatr. 2008;55:329\u201348.","journal-title":"Adv Pediatr"},{"key":"523_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1542\/peds.2009-3109","volume":"126","author":"G Lee","year":"2010","unstructured":"Lee G, Lorch S, Sheffler-Collins S, et al. National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics. 2010;126:204\u201313.","journal-title":"Pediatrics"},{"key":"523_CR4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1128\/CMR.00081-09","volume":"23","author":"M David","year":"2010","unstructured":"David M, Daum R. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23:616\u201387.","journal-title":"Clin Microbiol Rev."},{"key":"523_CR5","unstructured":"Teflaro\u00ae (ceftaroline fosamil) [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2016."},{"key":"523_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40121-013-0010-x","volume":"2","author":"D Shirley","year":"2013","unstructured":"Shirley D, Heil E, Johnson J. Ceftaroline fosamil: a brief clinical review. Infect Dis Ther. 2013;2:95\u2013110.","journal-title":"Infect Dis Ther"},{"key":"523_CR7","unstructured":"Pfaller MA, Mendes RE, Castanheira M, et al. Ceftaroline activity tested against bacterial isolates causing community-acquired respiratory tract infections and skin and skin structure infections in pediatric patients from United States hospitals: 2012\u20132014. Pediatr Infect Dis J 2016 Dec 12 (Epub ahead of print)."},{"key":"523_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/INF.0000000000001159","volume":"35","author":"C Cannavino","year":"2016","unstructured":"Cannavino C, Nemeth A, Korczowski B, et al. A randomized, prospective study of pediatric patients with community-acquired pneumonia treated with ceftaroline versus ceftriaxone. Pediatr Infect Dis J. 2016;35:752\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"523_CR9","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/INF.0000000000001160","volume":"35","author":"J Blumer","year":"2016","unstructured":"Blumer J, Ghonghadze T, Cannavino C, et al. A multicenter, randomized, observer-blinded, active-controlled study evaluating the safety and effectiveness of ceftaroline compared with ceftriaxone plus vancomycin in pediatric patients with complicated community-acquired bacterial pneumonia. Pediatr Infect Dis J. 2016;35:760\u20136.","journal-title":"Pediatr Infect Dis J"},{"key":"523_CR10","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1097\/INF.0000000000001191","volume":"35","author":"B Korczowski","year":"2016","unstructured":"Korczowski B, Antadze T, Giorgobiani M, et al. A multicenter, randomized, observer-blinded, active-controlled study to evaluate the safety and efficacy of ceftaroline versus comparator in pediatric patients with acute bacterial skin and skin structure infection. Pediatr Infect Dis J. 2016;35:e239\u201347.","journal-title":"Pediatr Infect Dis J"},{"key":"523_CR11","unstructured":"Forest Laboratories. Pharmacokinetics of ceftaroline in subjects 12\u201317\u00a0years of age. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. NLM Identifier: NCT00633126. https:\/\/clinicaltrials.gov\/ct2\/study\/NCT00633126. Accessed 5 Jan 2017."},{"key":"523_CR12","unstructured":"Forest Laboratories. Study of blood levels of ceftaroline fosamil in children who are receiving antibiotic therapy in hospital. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. NLM Identifier: NCT01298843. https:\/\/clinicaltrials.gov\/show\/NCT01298843. Accessed 5 Jan 2017."},{"key":"523_CR13","unstructured":"AstraZeneca. Safety, tolerability and efficacy of ceftaroline in paediatrics with late-onset sepsis. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. NLM Identifier: NCT02424734. https:\/\/clinicaltrials.gov\/show\/NCT02424734. Accessed 5 Jan 2017."},{"key":"523_CR14","unstructured":"Forest Laboratories. Ceftaroline diffusion into cerebrospinal fluid of children. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. NLM Identifier: NCT02600793. https:\/\/clinicaltrials.gov\/show\/NCT02600793. Accessed 5 Jan 2017."},{"key":"523_CR15","unstructured":"Baylor College of Medicine. Ceftaroline for treatment of hematogenously acquired Staphylococcus aureus osteomyelitis in children. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. NLM Identifier: NCT02335905. https:\/\/clinicaltrials.gov\/show\/NCT02335905. Accessed 5 Jan 2017."},{"key":"523_CR16","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1128\/AAC.02352-12","volume":"57","author":"T Riccobene","year":"2013","unstructured":"Riccobene T, Rekeda L, Rank D, Llorens L. Evaluation of the effect of a supratherapeutic dose of intravenous ceftaroline fosamil on the corrected QT interval. Antimicrob Agents Chemother. 2013;57:1777\u201383.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"523_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/jcph.809","volume":"57","author":"T Riccobene","year":"2017","unstructured":"Riccobene T, Khariton T, Knebel W, et al. Population PK modeling and target attainment simulations to support dosing of ceftaroline fosamil in pediatric patients with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. J Clin Pharmacol. 2017;57(3):345\u201355.","journal-title":"J Clin Pharmacol"},{"key":"523_CR18","unstructured":"Zinforo\u00ae (ceftaroline fosamil) [package insert]. S\u00f6dert\u00e4lje, Sweden: AstraZeneca AB; 2016."},{"key":"523_CR19","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jemermed.2011.05.035","volume":"42","author":"J Campagna","year":"2012","unstructured":"Campagna J, Bond M, Schabelman E, Hayes B. The use of cephalosporins in penicillin-allergic patients: a literature review. J Emerg Med. 2012;42:612\u201320.","journal-title":"J Emerg Med"},{"issue":"1","key":"523_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40121-016-0144-8","volume":"6","author":"J Yim","year":"2017","unstructured":"Yim J, Molloy L, Newlan J. Use of ceftaroline fosamil in children: review of current knowledge and its application. Infect Dis Ther. 2017;6(1):57\u201367.","journal-title":"Infect Dis Ther."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-017-0523-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0523-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0523-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:05:55Z","timestamp":1744715155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-017-0523-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,5]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["523"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0523-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,5]]},"assertion":[{"value":"5 April 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No source of funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AC and TS do not have any conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}